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With the goal of identifying hitherto unknown surface
exosites of streptokinase involved in substrate human plas-
minogen recognition and catalytic turnover, synthetic pep-
tides encompassing the 170 loop (CQFTPLNPDDDFRPGLK-
DTKLLC) in the-domainwere tested for selective inhibitionof
substrate human plasminogen activation by the streptokinase-
plasmin activator complex. Although a disulfide-constrained
peptide exhibited strong inhibition, a linear peptide with the
same sequence, or a disulfide-constrained variant with a single
lysine to alanine mutation showed significantly reduced capa-
bilities of inhibition. Alanine-scanning mutagenesis of the 170
loop of the -domain of streptokinase was then performed to
elucidate its importance in streptokinase-mediated plasmino-
gen activation. Some of the 170 loopmutants showed a remark-
able decline in kcat without any alteration in apparent substrate
affinity (Km) as compared with wild-type streptokinase and
identified the importance of Lys180 as well as Pro177 in the func-
tioning of this loop. Remarkably, these mutants were able to
generate amidolytic activity and non-proteolytic activation in
“partner” plasminogen as wild-type streptokinase. Moreover,
cofactor activities of the 170 loop mutants, pre-complexed with
plasmin, against microplasminogen as the substrate showed a
similar pattern of decline in kcat as that observed in the case of
full-length plasminogen, with no concomitant change in Km.
These results strongly suggest that the 170 loop of the-domain
of streptokinase is important for catalysis by the streptokinase-
plasmin(ogen) activator complex, particularly in catalytic proc-
essing/turnover of substrate, although it does not seem to con-
tribute significantly toward enzyme-substrate affinity per se.
Plasminogen activation, a key event in physiological
fibrinolysis, is a widely employed therapeutic means to rap-
idly alleviate circulatory disorders that arise due to obstruc-
tion of blood flow by pathological thrombi (1). Streptokinase
(SK),2 a bacteria-derived thrombolytic protein, activates plas-
minogen by forming a high affinity stoichiometric complex
with “partner” plasminogen, which, after a conformational acti-
vation step, acquires the capability to selectively cleave the
Arg561-Val562 scissile peptide bond in “substrate” plasminogen,
thereby converting the latter into HPN, plasmin (2, 3). Elegant
equilibrium binding and kinetic studies directed toward resolv-
ing the steps involved in the phenomenon of conformational
activation of HPG by SK demonstrate a relatively rapid forma-
tion of a SKHPG* complex, a “conformationally activated”
state, due to the generation of a nonproteolytically activated
active center, which is also amidolytically active (4). This con-
formationally activated SKHPG* complex can then recruit a
substrate molecule of HPG (3, 9) and proteolytically activate it,
likely through inter-molecular proteolytic scission, into HPN.
In addition, the HPGmoiety in the SKHPG* activator complex
can exchange with free HPN preferentially (because the latter
has been shown to have nearly three orders higher affinity for
SK) to formaSKHPNcomplex (the fullymature activator com-
plex) possessing strong HPG activation capability (5, 7) (Fig. 1).
One of the fascinating aspects of HPG activation reaction is the
molecular mechanisms whereby the binding of SK to HPN
modulates the substrate specificity of the latter (with, essen-
tially, a trypsin-like broad specificity), virtually re-program-
ming it to a very high degree of preference for theArg561-Val562,
the scissile peptide bond of substrate HPG that leads to the
HPG proteolytic activation (5–8). The crystal structure of SK
complexed with PN (the isolated catalytic domain of HPN),
with which SK forms a tight binary complex as it does with
full-length HPG, reveals that the domains of SK form a “three-
sided crater,” with the PN situated at the bottom of a valley
intowhich the substrate’s catalytic domain, bearing the “target”
scissile peptide bond to be cleaved, can potentially dock (9).
Besides the crystal structure, the crucial role of long range pro-
tein-protein interactions between the enzyme (SKplasmin)
and its macromolecular substrate HPG have become increas-
ingly clear through domain truncation studies on both SK and
HPG, and various other approaches (10–14). Interestingly, the
crystal structure of SKPN reveals that each of the three SK
domains contains a number of both defined and undefined
loops, some of which are positioned to potentially bind with
docked substrate plasminogen (9). An epitope in SK, the so-
called 88–97 loop of streptokinase -domain, has been identi-
fied recently (12) as being important in both 1:1 as well as ter-
nary, enzyme-substrate interactions. However, its overall
contribution toward plasminogen activation cannot be de-
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scribed asmajor, because itsmutationwas found to abolish only
a relatively small fraction of the overall activity of SKHPN
against HPG and PG. In addition to the 88–97 loop, the 250
loop, which is prominently located in a surface-accessible
region of the -domain so as to potentially interact with an
incoming substrate molecule (14), has also been implicated in
the interaction of the SKHPN activator complex with the krin-
gles of substrate HPG, particularly in terms of enhancing
enzyme-substrate affinity (14).Mutations in the 250 loop, espe-
cially the two lysine residues at its tip, have been demonstrated
to result in a 6- to 7-fold decrease in the affinity of the SKHPN
complex with the substrate by surface plasmon resonance as
well as steady-state kinetics, with little change in the kcat for
HPG activation (14). This loop has been shown to enhance the
affinity of SKHPG* and SKHPN catalytic complexes toward
substrate plasminogen through kringle-mediated interactions
(14), via the fifth kringle (15). It is notable, however, especially
judging from the quantitative catalytic contributions that both
these substrate interacting sites/exosites make toward catalysis
(12, 14, 15), that these are probably not sufficient in themselves
to fully account for the observed catalytic activity of the
SKHPN complex. This observation prompted us to look for
other potential exosites, particularly among the surface-located
loops, that could be important in the action of SK on human
plasminogen.
The location of the 170 loop in the crystal structure of
SK-PG (9, 16) suggests that this loop does not likely partic-
ipate in the formation of the binary complex, which hints at
its possible importance in interaction with substrate plas-
minogen. The present study, indeed, demonstrates for the
first time, a direct involvement of this loop in SK-mediated
catalysis through (i) competitive assays using synthetic peptides
derived from the loop sequence and (ii) alanine-scanning
mutagenesis of the various residues in the 170 loop. The results,
presented below, reveal that this loop contributes in a major
way toward catalytic processing of the substrate plasminogen,
because various point-mutations within this loop resulted in
more than an order of drop in kcat
even though substrate affinity of
themutants, as well as their capabil-
ity to engender the non-proteolytic
activation in partner plasminogen,
as tested through the activation of
scissile-peptide bond mutant of
microplasminogen (PG R561A)
remains unaltered. Thus, the pres-
ent study identifies a new exosite in
SK that is important in the activa-
tion of HPG.
EXPERIMENTAL PROCEDURES
Materials—Glu-plasminogen was
either purchased from Roche Diag-
nostics GmBH, Germany, or puri-
fied from human plasma by affin-
ity chromatography (17). The T7
RNA polymerase-promoter-based
expression vector, pET 23(d), and
Escherichia coli strain BL21 (DE3) were products of Novagen
Inc. (Madison, WI). Thermostable DNA polymerase (pfu
TurboTM) was obtained from Stratagene Inc. (La Jolla, CA).
Oligonucleotide primers were supplied by Biobasic Inc.,
Canada. Phenyl-agarose 6XLwas procured fromPrometic Bio-
sciences Ltd., UK, and DEAE-Sepharose (fast-flow) from
Amersham Biosciences. Urokinase, -aminocaproic acid, so-
dium cyanoborohydride, and L-lysine were purchased from
Sigma. All other reagents used were of the highest analytical
grade available.
Peptide Synthesis—Custom synthesis of the peptides derived
from the 170 loop primary structure, namely CQFTPLNPDD-
DFRPGLKDTKLLC, or its mutated sequence, namely CQFTP-
LNPDDDFRPGLADTKLLC, was carried out using standard
Fmoc (N-(9-fluorenyl)methoxycarbonyl)-based solid-phase
peptide chemistry on an automated peptide synthesizer model
PS3 by M/s USV, Mumbai, India. After synthesis and cleavage
by standard procedures, the peptides were purified on reverse
transcription-high-performance liquid chromatography and
disulfide-constrained peptide, were cyclized by H2O2 treat-
ment. Linear peptides were N-terminally acetylated and their
C-terminal amidated.
Design and Construction of Various SK Loop Mutants—The
SK gene from Streptococcus equisimilis H46A strain, a type C
streptococcus, was earlier cloned in pET 23d vector (11), and
this constructwas used to prepare all substitutionmutants. The
substitution point-mutations of the 170 loop of the -domain
of SK were prepared by using a QuikChange mutagenesis kit
obtained from Stratagene Inc., which involves usage of two
complementary primers having the desired mutation at the
center (see supplemental Table SI for a list of the primers
designed for the various mutants).
Expression and Purification of wtSK/SK Loop Mutants—The
wtSK and 170 loop mutants cloned in pET 23d were expressed
intracellularly in E. coli BL21 (DE3) cells as inclusion bodies
under the control of the T7 phage RNA polymerase promoter
FIGURE 1. Currently understood mechanism of plasminogen activation by streptokinase. SK forms an
equimolar complex with HPG (Pathway I) that leads to the generation of an active center in the complex
(SKHPG*)without cleavageof scissile peptidebond in thepartnerHPG. This “virgin complex” then recruits free
HPG as substrate and converts the latter into HPN. The HPN so formed rapidly exchanges with the HPG* from
SKHPG* complex due to its multifold higher affinity for SK in comparison to HPG. Alternatively, the SK can
directly combine with the HPN to make SKHPN activator complex (Pathway II). The activator complex then
catalytically acts on substrate HPGmolecules and converts them into HPN.
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after induction with isopropyl-1-thio--D-galactopyranoside,
and purified as described (11).
Preparation of HPN—Plasmin (HPN), the active form of
HPG, was prepared by digesting Glu-HPG with urokinase co-
valently immobilized on agarose beads using a ratio of 300
Plough units/mg HPG in 50 mM Tris-Cl, pH 8.0, 25% glycerol,
and 25 mM L-lysine at 22 °C for 10 h (11).
Preparation of PG—PG, the catalytic domain of plas-
minogen (residues Lys530–Asn790) made devoid of all five
kringles, was prepared by cleavage of HPG by HPN under
alkaline conditions (0.1 N glycine/NaOH buffer, pH 10.5) at
25 °C (18). Recombinant PG and its scissile peptide-bond
mutant, R561A, were expressed and purified as described ear-
lier (19).
Assays for Determining Inhibition of HPG Activator Activity
of Pre-formed wtSKHPN or Mutant SKHPN Complex by Pep-
tides Comprising 170 Loop Amino Acid Sequence/Mutated 170
Loop Sequence—TheSKHPNactivator complexwas formedby
preincubating equimolar concentrations (0.5 M each) of SK
and HPN in 50 mM Tris-Cl, pH 7.5, and 0.5% bovine serum
albumin at 22 °C for 1min (20). This enzyme complex, at a final
concentration of 5 nM, was added to reaction mixes already
containing various concentrations of individual peptides
(0–500 M) in assay buffer containing 50 mM Tris-Cl, pH 7.5,
and 100 mM NaCl preincubated with 0.05 M of HPG for 10
min. The generation of plasminogen activator activity was
measured spectrophotometrically at 405 nm by recording the
increase in rate of release of p-nitroanilide from the chromo-
genic substrate by the human plasmin generated as a result of
HPG activation for a period of 10 min at 22 °C. A control reac-
tion contained all components except the test peptide. The spe-
cific activity at each concentration of inhibitory peptide was
calculated by obtaining the slopes of the activation progress
curves as change in absorbance/t2. The extent of inhibition by
different concentrations of the given peptide was determined
and expressed in percentage relative to control reactions (taken
as 100%) conducted in the absence of peptide.
Assays for Studying the Activation of HPG by wtSK and SK
Mutants—A one-stage colorimetric assay method, was used to
measure the kinetics of HPG activation by wtSK or its mutants
(21). The change in absorbance at 405 nmwas thenmeasured as
a function of time (t) in a Molecular Devices Versamax micro-
plate reader at 22 °C. The activator activities were obtained
from the slopes of the activation progress curves as change in
absorbance/t2 (21).
N-terminal Methionine Removal from wtSK/170 Loop Mu-
tants—The N-terminal methionine was removed from wtSK
and 170 loop mutants using methionine aminopeptidase (pfu
MetAP) enzyme by a procedure, as described previously (22).
The extent of removal of theN-terminalmethionine was deter-
mined by N-terminal sequence analysis on Applied Biosystems
sequencer, Model 491A, and also through quantitative amino
acid composition analysis.
Esterolytic Activation of Equimolar HPGSK/170 Loop Mu-
tant Complex—Tomonitor the active site formation 7MHPG
was added to an assay cuvette containing 7.5 MwtSK/mutant,
100 M NPGB, and 10 mM sodium phosphate buffer, pH 7.5.
The “burst” of p-nitrophenol release due to acylation of active
center was monitored at 410 nm as a function of time at 22 °C
(2, 23, 24).
Amidolytic Activation by Equimolar wtSK/SK Loop Mutant
of R561A PGMutant—R561A PG mutant (final concentra-
tion, 5.0M)was incubatedwith 5.5MwtSKor amutant SK, in
0.5% bovine serum albumin, 50 mM Tris-Cl buffer, pH 7.5. The
time course of amidolytic activity generation was determined
after transferring an aliquot of the complex to a 100-l reaction
well containing assay buffer, 50 mM Tris-Cl, pH 7.5, 100 mM
NaCl along with 1 mM ChromozymPL (the transfer time
(including initial complexationwas30 s). Final concentration
of the complex in the amidolytic assay reaction was 10 nM. The
change in absorbance at 405 nm was monitored spectrophoto-
metrically as a function of time (19).
Determination of Steady-state Kinetic Constants for HPG/
PG Activator Activity of wtSK/SK Loop Mutants—The kinet-
ics of HPG/PG activation by HPNwtSK/SK-loop mutant
complexes wasmeasured by transferring suitable aliquots (usu-
ally, so as to attain a 0.5 nM final concentration in the assaymix)
of preformed HPNwtSK/SK loop mutant complexes to the
reaction wells containing varying concentrations of substrate
HPG/PG in assay buffer (50 mM Tris-Cl buffer, pH 7.5, and
100 mM NaCl) also containing 0.5 mM chromogenic substrate
ChromozymPL. The generation of activator activity wasmon-
itored at 22 °C at 405 nm as before. The kinetic parameters for
HPG/PG activation were then calculated from Michaelis-
Menten (v versus S) and inverse (1/v versus 1/S) Lineweaver-
Burk plots (20).
Kinetic Analysis of Protein-Protein Interactions by Surface
Plasmon Resonance-Ternary Interaction Analysis—A surface
plasmon resonance-based biosensor was also used to measure
the rate and equilibrium dissociation constants describing
interactions between soluble analytes (HPG and PG) and
wtSK/SK loop mutants complexed with immobilized HPG, a
situation simulating substrate binding to binary complex and
hereafter referred to as ternary interaction as described previ-
ously (14). Experiments were performed at 25 °C in HBS “run-
ning buffer” (30 mM Hepes, pH 7.4, 135 mM NaCl, and 1 mM
EDTA) supplemented with 0.05% Tween 20 and 5 mM NPGB.
The NPGBwas included to prevent plasmin-mediated proteol-
ysis (14) (see supplemental Figs. S4 and S5 for binding sensor-
grams). After subtracting the nonspecific response the associa-
tion rate constants (kon values), the dissociation rate constants
(koff values) and the equilibrium binding constant (KD) were
calculated from sensorgrams by non-linear fitting of the asso-
ciation and dissociation curves according to a 1:1 binding
model, using BIACORE 3000 evaluation software.
RESULTS ANDDISCUSSION
Selective Inhibition of the Activator Activity of the Preformed
wtSKHPN Enzyme Complex by Peptides Comprising Residues
165–185 of the Primary Structure of SK—With the objective to
explore the possible role of the 170 loop of SK in plasmino-
gen activation, a set of peptides was synthesized correspond-
ing to residues Pro165 to Leu185 (each containing 23 residues),
including unconstrained, linear, and peptides constrained at
the N and C termini through an intramolecular disulfide bond
(25) after cysteine additions at both ends (see “Experimental
Mechanism of Streptokinase Action
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Procedures” for details). The synthetic peptides were then
examined for their ability to selectively inhibit activation of sub-
saturating concentrations of substrate HPG by the preformed
wtSKHPN enzyme complex. Such a peptide mimotope
approach is closely similar to our earlier studies tomap another
important substrate-interacting site in SK (26, 27).
Remarkably, Peptide 2 (wild-type 170 loop sequence con-
strained through a disulfide bond) inhibited the activation of
substrate HPG in a concentration-dependent manner in the
low micromolar range of concentration, whereas the linear
peptide, i.e. Peptide 1, could not inhibit substrate HPG activa-
tion significantly compared with uninhibited controls (see Fig.
2 and supplemental Fig. S1 for actual progress curves showing
direct inhibition by the constrained peptide). This observation
indicated that the linear, 170 loop peptide probably remains
in an extended conformation incapable of competing with
SKHPN for its substrate interactions, whereas the cyclic pep-
tide adopts a conformation that mimics the 170 loop epitope in
the native structure of SK. Apart from testing for inhibition of
the preformed wtSKHPN enzyme complex, the two peptides
were tested for their ability to inhibit amidolytic activity of
HPN, on the one hand, and also the amidolytic activity of
SKHPN complex, on the other. In both cases, no observable
inhibition could be seen in the amidolytic activity of free HPN
aswell aswtSKHPNcomplex, which suggests that this 170 loop
peptide selectively interferes in the interaction of the activator
enzymewith substrateHPG, and thereby competitively inhibits
its activation.
Construction, Purification, and Functional Characterization
of Alanine Substitution Mutants of the 170 Loop of the -Do-
main of SK—The sequence of residues 170–181 of SK, which
comprises the 170 loop in the -domain of this tri-domain pro-
tein, consists of a stretch containing several positively and neg-
atively charged residues (16, 25). To further explore the possi-
ble role of this loop in SK-mediated plasminogen activation,
and also to identify its important residues if the loop were
indeed important in HPG activation, alanine substitution
mutations were introduced into the loop in the full-length
SK expressed in E. coli BL21 (DE3) cells as inclusion bodies
and purified to near-homogeneity (see “Experimental Proce-
dures” for details). Far-UV CD spectra of the purified 170 loop
mutants (data not shown) showed a close resemblance with
that of the wtSK, which was suggestive of the absence of any
major structural impairment caused by the loop mutations.
Themutants were then characterized for their ability to acti-
vate HPG by a single-stage continuous spectrophotometric
assay that measures the overall HPG activator activity using
catalytic amounts of SK and a large excess of HPG (28). The
relative slopes of the progress curves so obtained (see Fig. 3,
which shows the time course of plasmin generation by some of
the alanine mutants compared with that of wtSK) clearly indi-
cate that the alanine substitutionmutants of 170 loop exhibited
varied extents of reduction in their HPG activation capabilities.
Of all the single-site substitution mutants tested, we observed
that K180A exhibited the most compromised plasminogen
activator activity, roughly of an order of magnitude less com-
pared with wild-type SK. This was followed by P177A and
R176A, carrying substitutions toward the central region of the
loop. However, some mutants (D172A, D173A, and D174A)
showed, at most, only a minor decrease in activity compared
with wtSK.
Because alanine substitution at position 180 in the full-length
protein led to reduced plasminogen activation, it was of interest
to perform direct inhibition assays with wtSKHPN or mutant
SKHPN, as before, using the synthetic peptide approach. Using
170 loop wild-type peptide, both linear as well as cyclic, we
checked for a possible inhibition of the mutant K180AHPN
enzyme complex, but none of these exhibited any significant
inhibition at or near the concentrations seen to be inhibitory
FIGURE 2. Selective inhibition of substrate HPG activation ability of
wtSKHPNactivator complexby170 looppeptidemimotopes.Aliquots of
preformed SKHPN complex (5 nM) were added to HPG (0.05 M) in assay
buffer containing various concentrations of the 170 loop sequence peptides
(0–500 M). Residual percent activity in the presence of either linear, uncon-
strained 170 loop peptide (open circles), wild-type cyclic 170 loop peptide
(solid squares), linear K180Apeptide (solid circles), or the disulfide constrained
cyclic K180A peptide (solid diamonds), was calculated from the rates of plas-
min generated in the presence of peptide compared with that of activation
reaction (taken as 100%) where no peptide was added (see “Experimental
Procedures” for details). The control reactionswhereeitherplasmin inhibition
(in the absenceof SK)was tested in thepresenceof peptides are alsodepicted
(upward triangles), or where possible inhibition of SKHPN activator complex
in the absence of substrate plasminogen (downward triangles) are also
depicted.
FIGURE 3. Time course of single stage HPG activation assays by wtSK and
170 loopmutants.SK/various170 loopmutantsof SK (0.5nMeach)were added
individually to microtiter plate wells containing HPG and ChromozymPL,
and the activator activitiesweremeasured spectrophotometrically at 405 nm
as detailed under “Experimental Procedures.” The graph shows wild-type SK
(solid squares), R176A (solid circles), P177A (upward triangles), K180A (inverted
triangles), K180G (open circles), K180D (solid diamonds), and D181A (open
squares).
Mechanism of Streptokinase Action
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with wtSKHPN (data not shown). This result suggests that the
170 loop sequence derived (wild-type) peptide, which likely
mimics the specific conformation of the epitope present in the
170 loop of -domain in streptokinase, loses its recognition
(and, hence, capability for inhibition) once SK is mutated at the
180 position. To further explore the importance of this lysine to
alanine substitution, linear as well as cyclic synthetic peptides,
as before, carrying the alanine substitution at lysine 180 posi-
tionwere used to test for inhibition of wtSKHPN enzyme com-
plex in the HPG activation assays (Fig. 2; see also supplemental
Fig. S1 for actual progress curves showing no inhibition by the
mutated constrained peptide). From these results, it is apparent
that the mutated constrained peptide had lost its ability for
inhibition. Thus, overall, the results strongly support the con-
clusion that the 170 loop sequence represents a “hot spot”
involved in substrate activation by SKHPN.
Interaction of the 170 Loop Mutants of SK with Partner
HPG/PG—Because some of the single substitutionmutants of
the 170 loop exhibited significant reduction in their plasmino-
gen activator capability, as monitored through single-stage
assays, it was of interest to explore the underlying cause of this
decline in activity, i.e. whether it was the amidolytic/zymogen
activation step, which operates through Pathway I (schemati-
cally presented in Fig. 1) wherein 1:1 complexation ofHPGwith
SK and formation of the SKHPG* activator complex occurs,
was affected, or a step subsequent to this, in Pathway II, namely
the interaction of substrate HPG with the fully mature mutant
SKHPN complex. To address this issue, the ability of 170 loop
mutants to generate the active site in HPG upon 1:1 complex-
ation was examined through the well known reaction with the
active site acylating agent, which is characterized by a rapid
acylation of the active site in SK-HPG* marked by a burst of
color liberation (24). This enables one to detect the formation
of the activator complex even in the absence of proteolytic scis-
sion in the zymogen. Because amidolytic/esterolytic activation
of HPG through Pathway I requires the presence of an intact
N-terminal Ile (Ile1) in SK (19, 29, 30), it may bementioned that
the E. coli-derived, purified wtSK and the mutants had nearly
0.6 (14) mol of Ile per mole of protein as their N-terminal resi-
due, which indicates a fairly high level of intracellular process-
ing of the proteins by intrinsicE. coli fMet aminopeptidase (31).
Subsequent methionine depletion of purified wtSK and K180A
mutant under in vitro conditions was therefore carried out with
MetAP (see “Experimental Procedures” for details). This
resulted in further reduction of fMet to 0.1 mol/mol in both
proteins. When these samples were reacted with NPGB, a
nearly 2-fold jump in the extent of absorbance change for both
wtSK and K180A mutant was observed (data not shown). The
results presented in (Fig. 4) clearly show comparable acylation
by the 170 loop mutant (K180A) and that of wtSK, which is in
consonance with the results obtained through amidolytic acti-
vation of HPG, shown in supplemental Fig. S2. Closely similar
resultswere obtainedwith twoothermutants tested, namely SK
K180G and SK K180D (data not shown).
Likewise, the induction of a native-like complexation and
opening of the active site in partner moiety through the use of
the scissile peptide bond-mutated PG (R561A), which does
not transform to its plasminogen form, is also a test for Pathway
I capability (19, 29). Past studies have shown that the R561A
mutant ofPG can be activated by SKwithout being converted
to PN, and hence, can be utilized to rigorously test whether
Pathway I capability is intact or compromised in a given SK
mutant (19, 29). Accordingly, equimolar complexes of native
SK or K180A with PG R561A were tested (see “Experimental
Procedures”) in a continuous spectrophotometric assay for
amidolysis (Fig. 5). The results obtained clearly show the gen-
eration of nearly equivalent amidolytic activity upon addition of
either K180A mutant or wtSK to R561A PG mutant at 37 °C
(Fig. 5).
From these experiments, we can conclude that both wtSK as
well as the 170 loop mutants have equivalent capability to gen-
erate esterolytic/amidolytic activity (NPGB hydrolysis) in part-
ner HPG (see supplemental Fig. S2 for amidolytic activity gen-
eration in HPG), and therefore, the primary “functional lesion”
due to 170 loopmutagenesis does not impair active site creation
FIGURE 4. Active site titration of HPG upon complexing with wtSK/
K180A mutant using the active site acylating agent, NPGB. The figure
shows progress curves of NPGB hydrolysis as followed by p-nitrophenol
liberation by MetAP-treated wtSK (open upward triangles), and MetAP-
treated K180A (solid diamonds) complexes with HPG, and a control reac-
tion (solid squares) where no activator was taken (see “Experimental Pro-
cedures” for details).
FIGURE 5. Time course of the amidolytic activity generation in R561APG
by wtSK and K180A mutant. Equimolar SKR561A PG mutant and
K180AR561A PG mutant complexes were made, and catalytic amounts were
added to the assay buffer containing 1 mM chromogenic substrate
ChromozymPL, 50 mM Tris, pH 7.4, 100 mM NaCl, and amidolytic activity
generated was represented as wild-type SK (solid squares) or K180A mutant
(solid circles). Assayswere performed at 37 °Cwith 10 nM SK andPG complex
as described under “Experimental Procedures.”
Mechanism of Streptokinase Action
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by SK in partner HPG moiety during the formation of a fully
mature activator complex. This observation supports the con-
clusion that the reduced HPG activator capability observed
in the mutant SKHPN complexes arises from compromised
enzyme-substrate interactions, rather than catalytic events
related to 1:1 complexation of SK with HPG, and the matura-
tion of the latter to the SKHPN state.
Steady-state Kinetics of Plasminogen Activation by Equimo-
lar Complexes of the 170 Loop Mutants with Plasmin Shows
Selective Decline in Their Turnover Rates with No Concomitant
Change in Enzyme-Substrate Affinity—To identify the underly-
ing catalytic step that was affected in the various single substi-
tutionmutants of the 170 loop, steady-state kinetic studieswere
performed using a two-stage assay in which the Pathway II
capability, i.e. the ability of the SKHPN complex to act on sub-
strate HPG is measured selectively (32, 33). Equimolar com-
plexes of wtSK, or that of the individual 170 loopmutants, with
HPN were first made, and their catalytic amounts were then
employed as the enzyme complex for the activation of varying
substrate HPG concentrations. The progress of each reaction
was followed spectrophotometrically so as to obtain the steady-
state kinetic parameters (28). The results are shown in Table 1.
Interestingly, a nearly 10-fold drop in kcat was observed in the
case of the K180Amutant without any significant change in the
apparent affinity (Km) for substrateHPG (see supplemental Fig.
S3 for the plots). It may be mentioned here that the plasmin-
ogen activator (specific) activity of the 170 loop mutant
K180A remained compromised even when the mutant
enzyme complex used to activate substrate HPG was at con-
centrations up to nearly 1000-fold higher than the concen-
trations usually employed in these assays (data not shown). If
indeed the 1:1 affinity of the 170 loop mutants were compro-
mised (and their low activity was a result of a non-optimal asso-
ciation of the mutant with plasmin), the specific activity
obtained at say, the 100- and 1000-fold higher concentrations
of the enzyme would have tended to become like that of wtSK.
In contrast to K180A, themutant P171A, and the ones in which
the three consecutive aspartate residues were substituted with
alanines, namely D172A, D173A, and D174A, exhibited near-
native plasminogen activator activity. Once Pro177 was substi-
tuted with alanine, at the center of the loop, the resultant
mutant also showed an 8- to 10-fold drop in activity. From these
results, one can also infer that the proline side chain present in
the central region of the loop likely plays a role in maintaining
the functionality of this loop, because the deletion or alanine
substitution of Pro177 perturbed the functionality of the loop.
By contrast, proline at position 171 seemed to bear no func-
tional relevance, because the specific activity of P171A mutant
was essentially native-like. It is also noteworthy that, although
the activation rates decreased to nearly one-tenth of that of
wtSK by the lysine to alanine mutation at position 180, the
mutation of the residue next to 180 (i.e. D181A) “allowed” the
survival of nearly half the HPG activation capability seen with
wtSK. This suggests that Lys180 has an important role to play in
the functioning of the loop, along with Pro residue at position
177. Remarkably, the decrease in kcat seen with these mutants
did not result in any significant alteration in apparent substrate
affinity (to the extent that can be indicated byKm), which clearly
suggests that the functional role of the 170 loop is related to
generating substrate processivity in the SKHPN enzyme com-
plex rather than an overt role in macromolecular substrate
binding/docking. These results clearly suggest that the central
part, particularly residues in and around position 180, of the
170 loop is important for plasminogen activation.
Various other double- and triple-alanine substitution mu-
tants of the 170 loop were also constructed and examined for
their capability to process substrate HPG (Table 1). Interest-
ingly, from the results obtained, it became fairly evident that,
although the presence of lysine at position 180 is important
in the processing of substrate, other sites in the 170 loop are
also contributive to this phenomenon. It can be seen that the
mutation K180A, once in combination with other mutations
within the 170 loop, such as in the triple substitution mutant,
R176A/K180A/D181A, as well as the double substitution
mutants, namely R176A/K180A and P177A/K180A, while
essentially exhibiting the decline in catalytic turnover rates, still
retained a substrate affinity (Km) that was essentially compara-
ble to wild-type SK.
Probing the Importance of Lysine 180 in the 170 Loop of the
-Domain of Streptokinase—Because lysine to alanine muta-
tion at position 180 exhibited a markedly reduced ability to
activate substrate plasminogen by mutant SKHPN activator
complex, to substantiate our finding we examined whether a
positively charged side chain at this position wasmandatory for
activation of HPG. Accordingly, we prepared different side-
chain alteredmutants at position 180 and examined their kinet-
ics after complexationwithHPN. Interestingly, from the results
obtained (Table 1) it is evident that charge reversal mutation at
lysine 180, to aspartate, significantly decreased the activation of
HPG to levels25-fold lower as compared with wtSK (Fig. 3).
Glycine substitution at this position also resulted in a drop in
specific activity that was roughly comparable to the alanine
substitutionmutant, butmuch better than in the case of the Lys
to Asp mutation. Interestingly, when the residue was changed
to arginine, a rejuvenation of the original activator activity was
TABLE 1
Steady-state kinetic parameters for HPG activation by equimolar
complexes of SK or the various 170 loopmutants and HPN
The kinetic parameters for substrate HPG activation were determined at 22 °C with
the chromogenic substrate in 50 mM Tris-Cl buffer, pH 7.5, 100 mM NaCl as
described under “Experimental Procedures.” The data represent the mean of three
independent determinations.
Activator species Km kcat kcat/Km
M min1 min1M1
wtSK 0.40 0.05 7.50 0.3 19.00
P171A 0.40 0.04 7.00 0.5 17.50
D172A 0.50 0.06 7.00 0.5 14.0
D173A 0.50 0.08 7.10 0.4 14.2
D174A 0.50 0.07 6.50 0.3 13.0
R176A 0.60 0.06 4.50 0.4 7.5
P177A 0.45 0.08 0.80 0.03 1.7
K180A 0.50 0.03 0.70 0.01 1.40
D181A 0.55 0.06 3.50 0.34 6.3
K180D 0.50 0.06 0.20 0.06 0.4
K180G 0.60 0.05 0.60 0.04 1.0
K180R 0.50 0.07 3.20 0.50 6.4
177 pro del 0.60 0.05 0.80 0.06 1.3
R176A/K180A 0.60 0.08 0.70 0.15 1.2
R176A/D181A 0.40 0.07 4.00 0.45 10
P177A/K180A 0.50 0.07 0.70 0.02 1.4
K180A/D181A 0.50 0.06 0.80 0.03 1.4
R176A/K180A/D181A 0.60 0.08 0.40 0.04 0.6
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observed. Thus, the present study clearly highlights the impor-
tance of lysine 180 of the 170 loop of SK in catalytic processing
of substrate plasminogen, which is likely due to the require-
ment of a positive charge at this position. Interestingly, the two
amino acid residues identified to be relatively vital for 170 loop
functioning, namely Pro177 and Lys180, are phylogenetically
conserved across the various streptokinase allelic variant
“classes” (Fig. 6) despite the generally diverse sequence hetero-
geneity in this region of streptokinase (34, 35). This suggests the
evolutionary significance of these amino acid residues in the
170 loop that impart high catalytic turnover to SKplasmin.
Selective Interaction of the 170 Loop of Streptokinase with the
Catalytic Domain of Plasminogen—To obtain an idea of the
broad locale in substrate plasminogen with which the 170 loop
interacts, namely the catalytic domain or the kringle domains, a
few key substitution mutants of 170 loop were studied for their
ability to activate the isolated catalytic domain of plasminogen,
i.e.PG.We reasoned that if themutantswere affected in terms
of kringle-mediated enzyme-substrate interactions only, their
activity against PG as substrate would be unchanged, i.e. it
would be native-like. In contrast, if the mutants were compro-
mised with respect to functioning of the exosites on SK that
mediated enzyme-substrate interactions that were specifically
targeted toward the catalytic domain per se, one would expect
that their activity would be compromised similarly as observed
with HPG as the substrate, in relative terms with respect to
wtSK. It may be mentioned here that the activity of wtSKHPN
against PG as the substrate is only 1–2% that of HPG, but
once the full complement of the five kringle domains is present
next to the catalytic domain (as in native HPG), the activator
activity gets amplified to native-like levels (10). When the
steady-state kinetic parameters for wtSK/loop mutants, after
equimolar complexation with plas-
min, were examined, the obtained
results (Table 2) revealed a pattern
of decreased catalytic turnover,
compared with wtSK, which was
closely similar in relative terms to
that observed with full-length plas-
minogen as substrate. For example,
in the case of the mutant K180A,
which exhibits only one-tenth of the
catalytic turnover rate compared
with wtSK against native plasmino-
gen as the substrate, nearly the same relative declinewas seen in
its catalytic rates forPNgeneration fromPG, comparedwith
the rates seen with wtSK. The same pattern of decline in PG
processing was observed in other alanine mutants of the 170
loop aswell. All the alanine substitutionmutants exhibited aKm
of1–2M, which is about the same as that exhibited by wtSK,
but all of these mutants showed a pronounced decline in their
ability to catalytically convert PG to PN, which was mostly
similar to that seen when HPG was taken as the substrate.
The proline to alanine substitution mutant, as well as the
double mutant, P177A/K180A, showed a similar magnitude
of decline in processing of PG as that seen with HPG. Over-
all, these results suggest that the 170 loop of the -domain of
streptokinase encompasses a critical site of interaction
between the SKplasmin(ogen) complex and the catalytic
domain of substrate plasminogen.
Real-time Surface Plasmon Resonance Studies for Ternary-
mode Interactions of 170 Loop Mutants with Full-length and
Truncated Substrates—The foregoing results for decreased kcat
of the various 170 loop mutants for substrate HPG as well as
PG activation prompted us to explore whether the physico-
chemically measurable affinity of these substrates with pre-
formed activator complexes between HPG and wtSK, on the
one hand, and HPG with various 170 loop mutants, on the
other, were affected or not using the real-time surface plasmon
resonance technique. For this purpose, varying concentrations
of substrate HPG were “docked” onto the preformed binary
complex of immobilized HPG, and wtSK/various 170 loop
mutants on the sensor surface, as described earlier (10, 14). The
preformed SKHPG complex has been shown to be relatively
refractory to -aminocaproic acid, whereas the binding of the
activator complexwith the substrateHPG is susceptible to inhi-
bition in the low millimolar range of concentration (36). The
results obtained for the interaction of substrate HPG and PG
are given in Table 3. It is evident from the data that the equilib-
rium dissociation constants (KD) values for the ternary interac-
tion of substrate HPG were closely similar to that observed
earlier (14) in the case of ternary interaction of substrate HPG
with native full-length SK (0.1 M; see supplemental materi-
als for binding sensorgrams). It is notable that, despite their
lowered catalytic properties, the association and dissociation
rate constants for ternary interactions of the 170 loop mutants
were found to be closely similar to those observed in the case of
ternary interaction of substrate HPG with wtSK.
When the docking of the isolated catalytic domain of plas-
minogen, i.e. PG, was performed on the preformed binary
FIGURE 6.Multiple alignment of primary sequence of -domain depicting the 170 loop amino acid res-
idues of streptokinases secreted from S. equisimilis and three representative allelic variant clusters of
Streptococcus pyogenes, namely strains NS210, NS53, NS488, NS696, ALAB49, and NS13 (see Ref. 34).
Note that residues (all given in single-letter code) highlighted in bold type are conserved in 170 loop in all the
streptokinase polypeptides obtained from the different sources.
TABLE 2
Steady-state kinetic parameters forPG activation by equimolar
complexes of SK/SK 170 loopmutants and HPN
The kinetic parameters for substratePG activation were determined at 22 °C with
the chromogenic substrate in 50 mM Tris-Cl buffer, pH 7.5, 100 mM NaCl as
described under “Experimental Procedures.” The data represent the mean of three
independent determinations.
Activator species Km kcat kcat/Km
M min1 min1M1
wtSK 1.2 0.1 0.16 0.03 0.13
K180A 1.2 0.4 0.01 0.003 0.01
K180G 1.5 0.1 0.01 0.004 0.008
K180R 1.2 0.1 0.06 0.002 0.050
K180D 1.0 0.2 0.01 0.004 0.011
P177A 1.2 0.3 0.02 0.003 0.013
P177A/K180A 1.3 0.2 0.01 0.003 0.009
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complex of various 170 loop mutants with immobilized HPG,
the results demonstrated a native-like equilibrium dissociation
constant (KD) of the ternary interaction of substrate PG with
the three 170 loop mutants chosen for testing (Table 3). How-
ever, microplasminogen is known to be a poor substrate for the
SKplasmin(ogen) activator complex (14) with its reported KD
for binding in the ternary mode with the preformed SKHPG
complex being in the range of 1–2 M (14). Interestingly, the
real-time affinity measurements using surface plasmon reso-
nance analyses for the ternary interaction between PG as the
substrate and 170 loop mutant complexed with immobilized
HPG show equilibrium dissociation constants (1.0 M) that
are nearly similar to that of wtSK. These results thus support,
on a direct physicochemical level, the observations obtained
from the steady-state kinetics studies that the 170 loop, al-
though essential for catalytic processing of substrate plasmin-
ogen, does not seem to be contributive substantially toward
enzyme-substrate affinity per se.
Even though the present study does not elucidate the exact
molecular mechanism by which the 170 loop contributes to
catalytic turnover, the observations are suggestive of the fact
that the 170 loop interacts specificallywith the catalytic domain
of substrate. Surprisingly, this interaction does not seem to con-
fer a high degree of enzyme-substrate affinity, because these
mutants, after complexation with HPN/HPG, maintain a
native-like docking potential for the macromolecular sub-
strates but seemdeficient in the post-docking phase of catalysis.
These results complement a similar observation regarding the
exclusivity of the substrate docking and turnover steps in this
enzymatic system, wherein it was shown that the Asp41–His48
region of SK is involved in binding to substrate plasminogen
independent of catalytic efficiency of its active binary complex
(37).
The currently favored “exosite” model of SK action (4, 7, 9,
12, 14, 15, 36) envisions an “active valley” in the SKHPN com-
plex, with the trypsin-like plasmin active center located at its
base. The involvement of exosite residues in proteinases of the
blood coagulation pathway is well demonstrated in literature
(38), an elegant example being that of the prothrombinase com-
plex (39, 40), wherein substrate specificity, effector recognition,
molecular activation, and regulation of thrombin (41, 42) are
modulated by surface exosites unlike, say, a protease such as
chymotrypsin, which acts primarily through the active site
region (43). It is interesting to note that the role of the 170
loop-located exosite in SK action seems to be solely mediated
through effects on the catalytic turnover of the SKPN enzyme
complex. In contrast, the exosite resident in the 250-loop seems
to be operative also through direct substrate binding (14). It
thus appears that SK possesses at least two types of exosites,
namely one or more directed to substrate docking (character-
ized by “Km effects”), and “pure” kcat effects, as in the case of the
170 loop. The exact molecular mechanism whereby such
exosites augment the catalysis by SKHPN is not clear at this
stage, but thismay be through subtle changes in and around the
active site of the SK-bound plasmin, which improve access to
the substrate, or conversely, release of product, especially in the
region around the scissile peptide bond in the macromolecular
substrate. Thus, it is conceivable that the HPN active center
remains essentially as “non-committal” with respect to its pri-
mary substrate specificity as is free HPN, but the overall
SKplasmin complex acquires a selective substrate-processing
capacity through the stereochemically guided docking of the
macromolecular substrate into this valley. Once this is accom-
plished, it is logical to assume that facile proteolytic cleavage
could now occur at the substrate’s scissile peptide bond, trig-
gering the product expulsion step of catalysis. The exact iden-
tity of all exosites participating in this interaction, which also
involves long range enzyme-substrate interactions as well (10),
is not known currently. Nevertheless, this model is consistent
with a mechanistic scenario wherein the 170 loop or, indeed,
any other such surface-located, substrate-interacting site(s) on
SK, such as the 250-loop or the 88–97 loop (12, 14) act as flex-
ible pivots, or hinges, that facilitate the rapid release of the
product from the enzyme at the end of each catalytic cycle even
if such an interaction may, or may not (as in case of the 170
loop) necessarily be contributive in terms of enhancing en-
zyme-substrate affinity. Indeed, one such site, which does con-
tribute toward enzyme-substrate affinity, has already been
identified to reside in the fifth kringle ofHPG (14, 15).However,
the interacting site for the 170 loop in substrateHPGnowneeds
to be identified to closely examine the dynamics of their inter-
action. Efforts along these lines, using fluorescence resonance
energy transfer and cross-linking studies, are currently under-
way in our laboratory. Besides SK, the role of surface-located
loops in plasminogen activation has been strongly indicated in
other bacterial and physiological activators as well, such as
staphylokinase, tissue plasminogen activator, and urokinase
plasminogen activator (44–46), but the exact manner whereby
such loops modulate enzymatic specificity and/or catalysis
remains to be satisfactorily elucidated. Such an understanding,
TABLE 3
Association (kon) and dissociation (koff) rate constants and apparent equilibrium dissociation (KD) constants for the interaction of substrate
plasminogen andPG with wtSK/SK loopmutants complexed with immobilized HPG by SPR
Kinetic constants for the interaction of substrate HPG and PG with wtSK/loop mutants: HPG (binary complex) were determined by global fitting to a 1:1 binding model,
using the BIAcore 3000 evaluation software as described under “Experimental Procedures.” A stable binary complex betweenwtSK/SK loopmutants andHPG immobilized
onto the SA chipwas firstmade, and the binding of varying concentrations of substrateHPG (0.05–1M), or substratePG (1–6M)wasmonitored (also see supplemental
Figs. S2 and S3 for the sensorgrams).
Ligand Ligate HPG Ligate PGkon koff KD kon koff KD
M1s1 105 s1 101 M 106 M1s1 105 s1 101 M 106
wtSKHPG 12 1.5 1.8 0.2 0.15 0.03 1.4 0.5 1.5 0.20 1.1 0.3
P177AHPG 8.0 1.8 1.6 0.2 0.20 0.04 1.5 0.3 1.7 0.15 1.1 0.2
K180AHPG 11 2.0 1.5 0.3 0.14 0.02 1.1 0.3 1.4 0.15 1.2 0.2
K180DHPG 12.5 2.0 1.5 0.4 0.12 0.02 1.2 0.2 1.2 0.15 1.0 0.2
Mechanism of Streptokinase Action
NOVEMBER 20, 2009•VOLUME 284•NUMBER 47 JOURNAL OF BIOLOGICAL CHEMISTRY 32649
 by guest, on June 4, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
undoubtedly, will be helpful in the redesign of existing plasmin-
ogen activators, and perhaps, also in the de novo design of pro-
teases with new substrate specificities. In our current working
model of SK action, it is the co-operative action of the various
exosites that leads to the generation of high rates of plasmino-
gen activation by SK, which is known to be highest among all
other physiological and bacterial PG activators (47). Our pre-
liminary observations3 with simultaneous multisite mutations
in the various exosites of SK identified so far, on the one hand,
and sites in the macromolecular substrate that are appreciably
distant from the scissile peptide bond, on the other, reveal
highly synergistic effects on the catalytic rates for HPG activa-
tion. These observations are intriguingly indicative of a cata-
lytic mechanism that is centered on the existence of a “distrib-
uted” network of exosites in the SKHPN enzymatic complex.
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